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Stimulant and non-stimulant drugs can reduce symptoms of attention deficit/hyperactivity disorder (ADHD). The stimulant drug
methylphenidate (MPH) and the non-stimulant drug atomoxetine (ATX) are both widely used for ADHD treatment, but their
differential effects on human brain function remain unclear. We combined event-related fMRI with multivariate pattern recognition to
characterize the effects of MPH and ATX in healthy volunteers performing a rewarded working memory (WM) task. The effects of MPH
and ATX on WM were strongly dependent on their behavioral context. During non-rewarded trials, only MPH could be discriminated
from placebo (PLC), with MPH producing a similar activation pattern to reward. During rewarded trials both drugs produced the
opposite effect to reward, that is, attenuating WM networks and enhancing task-related deactivations (TRDs) in regions consistent with
the default mode network (DMN). The drugs could be directly discriminated during the delay component of rewarded trials: MPH
produced greater activity in WM networks and ATX produced greater activity in the DMN. Our data provide evidence that: (1) MPH
and ATX have prominent effects during rewarded WM in task-activated and -deactivated networks; (2) during the delay component of
rewarded trials, MPH and ATX have opposing effects on activated and deactivated networks: MPH enhances TRDs more than ATX,
whereas ATX attenuates WM networks more than MPH; and (3) MPH mimics reward during encoding. Thus, interactions between drug
effects and motivational state are crucial in defining the effects of MPH and ATX.
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INTRODUCTION
Stimulant and non-stimulant medications that influence
dopamine (DA) and noradrenaline (NA) neurotransmission
can reduce symptoms of attention deficit/hyperactivity
disorder (ADHD). The stimulant drug methylphenidate
(MPH) has been shown to have consistently greater clinical
efficacy than atomoxetine (ATX), a non-stimulant drug
recently approved for the treatment of ADHD in the USA
and Europe (Spencer et al, 1998; Michelson et al, 2001;
Faraone et al, 2005; Kemner et al, 2005; Starr and Kemner,
2005; Newcorn et al, 2008). ATX nonetheless offers several
potential advantages over MPH, including reduced abuse
liability, reduced risk of motor side effects and as an
alternative treatment for patients non-responsive to stimu-
lants (Newcorn et al, 2008). However, the mechanisms
underlying their differences on human brain function are
unclear.
There is converging evidence that weakened prefrontal
cortex (PFC) function underlies several of the hallmark
deficits in ADHD (Arnsten, 2006). In particular, working
memory (WM)Fthe ability to hold and manipulate informa-
tion for future actionFis impaired in ADHD (Martinussen
et al, 2005; Willcutt et al, 2005) and has been strongly linked
to the activity of the catecholamines (DA and NA) within the
PFC (Brozoski et al, 1979; Arnsten and Goldman-Rakic,
1985). WM performance is also known to be improved with
MPH (Elliott et al, 1997; Bedard et al, 2004; Mehta et al,
2004), currently understood as resulting from an increased
efficiency of frontoparietal WM regions shown using PET
neuroimaging studies (Mehta et al, 2000; Schweitzer et al,
2004). Studies in experimental animals suggest that ATX has
a similar ability to improve WM function (Gamo et al, 2010),
via effects on prefrontal cortical activity, although there are
no comparative human neuroimaging studies of the effects of
MPH and ATX on WM networks.
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that: (1) MPH inhibits both DA and NA transporters
(DAT and NAT, respectively; Seeman and Madras, 1998;
Han and Gu, 2006); (2) ATX is a selective inhibitor of NAT
(Wong et al, 1982; Bolden-Watson and Richelson, 1993);
and (3) both drugs increase concentrations of DA and NA in
the PFC, but only MPH increases DA in the striatum
(Bymaster et al, 2002). However, the neural consequences of
these differential actions in human beings and their
implications for functional brain networks are currently
unknown.
Theoretically, systemically administered MPH and ATX
may differentially influence distributed brain regions due to
localized effects at DAT and NAT sites (Ciliax et al, 1999;
Schou et al, 2005) and consequent effects on connected
brain areas, in addition to the differential effects on striatal
catecholamine neurotransmission shown in rodents (By-
master et al, 2002). Thus, differential effects of MPH and
ATX may be distributed across multiple brain regions.
Multivariate pattern recognition (PR) methods are sensitive
to such spatially distributed information by making use of
the correlation between brain voxels and afford substan-
tially greater sensitivity than conventional mass-univariate
analysis methods (Haynes and Rees, 2006; Kriegeskorte
et al, 2006; Norman et al, 2006). Therefore, we combined
event-related fMRI with a novel whole-brain PR analytic
approach to characterize and discriminate acute effects
of MPH and ATX in healthy volunteers performing
a WM task. Although we expected reductions in PFC
activity after MPH, this study represents the first attempt
to: (1) examine the effects of ATX on WM networks and
(2) test potential differences between prefrontal cortical
and striatal activation following administration of MPH and
ATX in humans.
Finally, recent literature suggests an important contribu-
tion of reward to the regulation of WM-related brain
activity (Ichihara-Takeda et al, 2010). This accords with
evidence that both reward and MPH have similar effects on
sustained attention task performance in ADHD (Trommer
et al, 1991; Andreou et al, 2007). Therefore, we also explored
the role of reward on WM function, with a focus on
determining its impact on our ability to discriminate MPH
and ATX.
METHODS
Participant Recruitment and Data Acquisition
Fifteen healthy male university students and members of
the general public (aged 20–39 years) were recruited by
local advertisement and were scanned on three occasions.
Participants were screened by interview and physical exam
for previous or current medical, psychiatric, or neurological
problems. Other exclusion criteria included any substance
abuse history, smoking 45 cigarettes per day, and
consuming the equivalent of 45 cups of coffee per day.
Participants were trained on the WM task on the screening
day and were asked to refrain from alcohol and caffeine
containing products for 24h before dosing. Participants
provided written informed consent and the study was
approved by South London Research Ethics Committee 3.
On each scanning day, participants were screened for
drugs of abuse and alcohol, and then each participant
received an oral dose of MPH (30mg), ATX (60mg),
or a placebo (PLC) according to a randomized, double-
blind Latin square design. Doses of MPH and ATX
were chosen to approximately match doses used in
clinical practice, and doses reported in the literature (eg,
Gilbert et al, 2006).
Scanning was performed on a General Electric Signa
HDx 3T scanner and was timed to coincide with the peak
plasma concentration for MPH and ATX (Wargin et al,
1983; Sauer et al, 2005). Between 90 and 135min post-dose,
six resting state arterial spin labelling scans were acquired,
which will be reported separately. Approximately 135min
post-dose, gradient-echo (GE) echoplanar imaging was
used to acquire 450 whole-brain images while participants
performed a WM task (TR¼2s, TE¼30ms, FA¼751,
38 3-mm-thick near-axial slices with 0.3mm gap,
in-plane resolution¼3.75 3.75mm). A high-resolution
GE structural scan was also acquired for each participant
to assist accurate registration to a standard space (TR¼3s,
TE¼30ms, FA¼901, 43 3-mm-thick near-axial slices with
0.3mm gap, in-plane resolution¼1.88 1.88mm).
WM Task
During the WM task, 40 trials were presented with an inter-
trial interval of 8 or 10s, and during each trial, participants
were required to remember the spatial location of a target
stimulus (a dot) relative to a fixation cross. The task allowed
each WM component process (encoding, delay, and
retrieval) to be separately coded (Figure 1). Half the trials
carried a monetary reward, indicated by the color of the
stimulus and the order of trials was randomized and
counterbalanced across participants. During encoding (2s),
the target stimulus was presented, followed immediately by
a mask to disrupt visual iconic memory. After a variable
length delay (7 or 9s), the target and an additional
distractor stimulus were presented and participants in-
dicated which of the stimuli matched the target location
by left or right button press on a two-button response
box (retrieval). At the conclusion of the trial, feedback
was provided, indicating success or failure and accuracy
and response time (RT) were recorded. Acquisition was
optimized for volume-based PR, with stimuli presented
in a TR-locked manner, which ensures that data vectors
were sampled from approximately the same point on the
hemodynamic response curve and helps to generate a
consistent response pattern for each trial. The task was
written in VB.net, presented via projector to a screen at the
end of the scanner bed and viewed by participants through
mirrors attached to the head coil. Participants completed a
visual analog scale (VAS; Bond and Lader, 1974) at four
time points during each visit to record their subjective
experience, which contained 16 items that were later
collapsed to reflect two subjective factors: ‘alertness’ and
‘tranquility’ (Herbert et al, 1976; Supplementary Material).
Outside the scanner, VAS responses were measured
with a ruler and inside the scanner a computerized VAS
was administered where participants recorded their re-
sponses by moving a sliding cursor using the two-button
response box.
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FMRI data were realigned, spatially normalized, and smoothed
with an isotropic 8mm Gaussian kernel using statistical para-
metric mapping software version 5 (SPM5) (www.fil.ion.ucl.ac.
uk/spm). Additional pre-processing was performed in Matlab
(www.mathworks.com), which consisted of linearly de-
trending the data and applying a whole-brain mask to
select intracerebral voxels. Classifier samples were con-
structed by: (1) shifting the onset of each trial by one
volume to accommodate the hemodynamic delay; (2)
converting brain volumes acquired during each task
component to vectors; and (3) averaging two (encoding,
retrieval, and shorter delay) or three (longer delay)
consecutive volumes from each WM component. We
averaged at least two volumes for each WM component to
accommodate the temporal blurring induced by the
hemodynamic response and to ensure that we captured
the peak of the hemodynamic response. Trials where each
participant responded incorrectly were excluded and
remaining trials were averaged to construct a single mean
sample per participant (averaged over approximately 16
correct trials). We constructed classifier samples for the
baseline condition by extracting and averaging two volumes
during the fixation period between trials (6–8s after the end
of feedback).
Classifier Implementation
We used binary Gaussian process classifiers (GPCs;
Rasmussen and Williams, 2006) to classify: (1) each WM
component from baseline; (2) rewarded from non-rewarded
trials; and (3) each drug condition (ATX, MPH or PLC)
from one another. GPCs are kernel classifiers similar to
support vector machines (SVMs) that have good perfor-
mance for fMRI (Marquand et al, 2010b). The main
advantage of GPCs over SVMs is that GPCs provide
probabilistic predictions and estimates of predictive un-
certainty. Theoretical background and implementation
details for GPCs have been presented elsewhere (Rasmussen
and Williams, 2006; Marquand et al, 2010b), but a brief
description is provided in Supplementary Material. In this
work, we use linear kernel GPCs that help prevent
overfitting and allow direct extraction of the weight vector
as an image.
Recursive Feature Elimination
We embedded all classifiers contrasting reward or drug
state in a recursive feature elimination (RFE; Guyon et al,
2002), which is a backward elimination feature selection
approach that aims to find a set of features (voxels) by
iteratively removing the least informative features. RFE
was originally developed for SVM (SVM-RFE), and has
been applied to multiple fMRI studies (eg, De Martino
et al, 2008; Formisano et al, 2008; Hanson and Halchenko,
2008), but here we adapt it to GPC (‘GPC-RFE’; Marquand
et al, 2010a). RFE starts by creating an ‘active feature
set’, initially containing all cerebral voxels. A classifier is
trained repeatedly on the active set and at each iteration
features are ranked and a subset of the lowest ranking
features is removed (2% of voxels), which continues
until no features remain. Predictive performance is
measured at each stage of feature removal on an
independent sample, allowing an optimal number of
features maximizing predictive performance to be selected
(Supplementary Material). RFE is most commonly applied
because it modestly increases accuracy, but here our main
motivation was because it yields a spatially sparse multi-
variate map (akin to a thresholded statistical parametric
map), which is essential to prevent falsely inferring a brain
region is functionally important when in fact it is not. RFE
is a principled approach to achieve this aim and is more
appropriate than an arbitrary voxel-wise threshold because
it: (1) validates the multivariate pattern against predictive
accuracy; (2) accommodates the multivariate structure of
the pattern; and (3) does not require specification of an
arbitrary threshold level. We did not apply GPC-RFE to the
classifiers contrasting task and baseline, because this is a
trivial classification problem and the objective was only to
define the brain activity pattern evoked by the task for
which an unthresholded map is preferable, but for reference
Figure 1 Delayed match to location working memory (WM) task. Note that the only difference between rewarded and non-rewarded trials is the
color of the stimulus.
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brain classifiers trained to discriminate between all experi-
mental contexts (Supplementary Material).
Cross-Validation
RFE can be viewed as a model selection problem, where
model complexity is determined by a single parameter (the
number of features to retain), which must be set without
using the test data set to avoid overfitting. To achieve this,
we used nested leave-one-out cross-validation (LOO-CV),
which uses a three-way split of the data to provide an
unbiased estimate of generalization ability while also
allowing unbiased parameter estimation. For each LOO-
CV fold, we excluded all data for a single participant for the
test set, then repeatedly repartitioned the remaining 14
participants into a validation set (one participant) and
training set (13 participants). We selected the optimal
number of features on the validation set before applying it
to the test set.
Visualization of the Differential Activity Pattern
To visualize the differential activity patterns, we retrained
each GPC-RFE classifier using all participants’ data, for
which the optimal number of features was the mean across
all training folds. For this application, we are interested in
knowing how brain activity differs between experimental
classes rather than providing a representation of the
decision boundary, so we did not visualize classifier
weights, which is common in PR (Mourao-Miranda et al,
2005). Instead, we employed a mapping approach that
enables direct visualization of the relative class distribution,
where the coefficient scores at each voxel represent the
relative difference between experimental classes in the




Repeated-measures ANOVA revealed that time (RT) did not
differ between drugs (F2,28¼0.001, p¼0.99), or between
rewarded and non-rewarded trials (F1,14¼0.003, p¼0.96),
and there was no reward drug interaction (F2,28¼0.47,
p¼0.63). Participants made fewer errors on rewarded
relative to non-rewarded trials (F1,14¼11.54, po0.01), but
errors did not differ between drug conditions (F2,28¼0.12,
p¼0.89) and there was no reward drug interaction
(F2,28¼1.80, p¼0.19). A summary of RT and accuracy is
provided in Supplementary Table S1.
Subjective Measures
Several participants reported side effects to the administra-
tion of the drugs (eg, nausea, drowsiness), but these were
mild in all cases and mostly resolved before discharge on
the study day. Subjective factors of alertness and tranquility
were investigated as potential confounds to any drug effect
using an independent repeated-measures ANOVA for each
factor. For alertness, there was no main effect of drug
(F2,28¼0.59, p¼0.56), but a main effect of time point was
observed (F1,14¼8.83, p¼0.01), whereby post-dose VAS
scores were slightly lower than pre-dose scores across all
drug conditions. No drug time point interaction was
found (F2,28¼0.21, p¼0.81). For tranquility, there was no
main effect of drug (F2,28¼1.78, p¼0.19) or time point
(F1,14¼0.02, p¼0.88) and no interaction effect (F2,28¼0.48,
p¼0.62).
Task Networks
Whole-brain classifiers accurately discriminated each WM
component process from baseline for all drug conditions
(mean accuracy (SEM) of 18 classifiers: 97.61% (0.01);
po0.01, binomial test). As noted, the magnitude of GPC
coefficients at each voxel provides a measure of the relative
difference in blood oxygen level-dependent (BOLD) activa-
tion between classes in the context of the entire discrimi-
nating pattern and the sign indicates (‘favors’) the class with
greater mean activation (Marquand et al, 2010b). GPC
distribution maps (Supplementary Figures S1 and S2)
revealed a distributed network (pattern) favoring the task
component processes, including bilateral intraparietal sulci
(IPS; Brodmann area (BA) 7), middle frontal gyri (BA 9/46),
and bilateral medial and inferior frontal gyri (BA 6 and 47,
respectively) in addition to visual and motor cortical
regions. The pattern favoring baseline (task-related deacti-
vationsFTRDs) included regions comprising the default
mode network (DMN), that is, posterior cingulate cortex
(PCC; BA 30), precuneus (BA 31), medial PFC (BA 9/10 and
32), and lateral parietal cortex (BA 39).
Classification of Reward
Classification accuracy for GPC-RFE classifiers discriminat-
ing between rewarded and non-rewarded trials exceeded
chance (50%) for all WM component processes and across
all three drug conditions, with the exception of the encoding
component on MPH (mean (SEM) of six classifiers: 70.72%
(0.04); Figure 2a). The pattern favored reward and
encompassed both the WM networks and TRDs described
above. Specifically, BOLD activity in lateral PFC, parietal
regions, medial PFC, and PCC/precuneus was relatively
increased (Figure 3; Supplementary Figure S2); in other
words, the effect of reward was to attenuate TRDs and
enhance activity in the WM network. TRDs were most
prominently attenuated during encoding and delay compo-
nents of the rewarded WM task, whereas visual and WM
regions were most prominently enhanced during delay and
retrieval components of the task (see Figure 3). In summary,
reward produces a generalized increase in BOLD activity,
including both task-related activations (which increase with
reward) and TRDs (which are suppressed with reward).
Classification Accuracy for Drug Contrasts
For ATX vs PLC, classification accuracy exceeded chance for
encoding, delay, and retrieval components of rewarded
trials (po0.05), but not during any WM component for the
non-rewarded trials (Figure 2b). For MPH vs PLC, accuracy
exceeded chance during encoding, delay, and retrieval of
rewarded trials and during encoding of non-rewarded trials
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accuracy exceeded chance for the delay component of
rewarded trials (po0.05; Figure 2d).
For all classifiers exceeding chance, RT data were used
to explore putative relationships between classifier perfor-
mance and behavior. No significant correlations between
RT and GPC-RFE predictive probabilities were found. Note
that correlations with performance accuracy were not appro-
priate because all participants were well trained and made
only a small number of errors, and only correct trials were
included in the image analysis.
Discriminating Pattern for ATX vs PLC
(Rewarded Trials)
Maps derived from classifiers trained to discriminate ATX
from PLC on rewarded trials (Figure 4) contained a
distributed pattern favoring PLC that included WM net-
works and DMN; in other words, in the reward context, ATX
attenuated BOLD activity in WM networks and enhanced
TRDs. During encoding, the pattern favoring PLC included
the DMN (medial PFC and PCC/precuneus) and WM
networks (IPS and bilateral PFCFBA 9, 46, and 47). In
Figure 2 Classification accuracy for Gaussian process classifier (GPC)-recursive feature elimination (RFE) classifiers for (a) rewarded vs non-rewarded
trials, (b) atomoxetine (ATX) vs placebo (PLC), (c) methylphenidate (MPH) vs PLC, and (d) MPH vs ATX. Asterisks indicate results significantly different
from chance, that is, 50% (po0.05, binomial test).
Figure 3 Gaussian process classifier (GPC)-recursive feature elimination (RFE) distribution maps for classifiers discriminating between rewarded and
non-rewarded trials for each working memory (WM) component (placebo (PLC) arm). (a) Encoding, (b) delay, and (c) retrieval. Maps were rescaled
such that the absolute maximum coefficient score was ±1. The magnitude of Gaussian process classifier (GPC) coefficients provides a measure of the
relative difference in BOLD activity between experimental classes (in the context of the entire pattern) and the sign favors the class with greater mean
activity. A distributed pattern favoring reward can be observed that indicates: (1) reward increased activity throughout WM networks and across all WM
component processes and (2) reward-attenuated task-related deactivation (TRDs) in default mode network (DMN) regions, which was especially
prominent during encoding and delay.
fMRI patterns for methylphenidate and atomoxetine
AF Marquand et al
1241
Neuropsychopharmacologyaddition, small clusters weakly favoring ATX were observed
in the cerebellum and lateral PFC during encoding. During
delay and retrieval components, the pattern favoring PLC
was most prominent in WM regions.
Discriminating Pattern for MPH vs PLC
(Rewarded Trials)
Maps derived from classifiers trained to discriminate MPH
from PLC on rewarded trials (Figure 5) contained a
distributed pattern favoring PLC similar to that observed
for ATX, which also encompassed WM and DMN regions.
During encoding, the pattern favoring PLC was mostly
localized to DMN regions, but during delay and retrieval,
the PLC pattern additionally included clusters in WM,
motor, and visual regions, and was most widespread during
retrieval. The pattern favoring MPH was restricted to
encoding and was localized mostly to the cerebellum and
lateral PFC.
Discriminating Pattern for MPH vs PLC
(Non-Rewarded Trials)
The map derived from the classifier trained to discriminate
MPH from PLC during the encoding component of non-
rewarded trials (Figure 6) contained a distributed pattern,
this time favoring MPH, including DMN, WM (eg, IPS), and
visual regions. Thus, in the absence of reward, MPH
enhanced activity in WM networks and attenuated TRDs.
Note that the map contrasting MPH and PLC shows a strong
qualitative similarity to the one contrasting rewarded and
Figure 4 Gaussian process classifier (GPC)-recursive feature elimination (RFE) distribution maps for classifiers discriminating between atomoxetine (ATX)
and placebo (PLC) conditions for each working memory (WM) component (rewarded trials). (a) Encoding, (b) delay, and (c) retrieval. A distributed pattern
favoring PLC can be observed that indicates that in a rewarded context: (1) ATX attenuated activity throughout WM networks, which was most prominent
during delay and retrieval and (2) ATX enhanced task-related deactivations (TRDs) in default mode network (DMN) regions across all WM component
processes. The cerebellum was the only region favoring ATX and was only observed during encoding.
Figure 5 Gaussian process classifier (GPC)-recursive feature elimination (RFE) distribution maps for classifiers discriminating between methylphenidate
(MPH) and placebo (PLC) for each working memory (WM) component (rewarded trials). (a) Encoding, (b) delay, and (c) retrieval. A distributed pattern
favoring PLC can be observed that indicates that in a rewarded context: (1) MPH attenuated activity throughout WM networks, which was most prominent
during delay and retrieval and (2) MPH enhanced task-related deactivation (TRDs) in default mode network (DMN) regions across all WM component
processes. The only regions favoring MPH were found during encoding and included cerebellum and small regions of lateral PFC.
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condition (Figure 3a).
Discriminating Pattern for MPH vs ATX (Rewarded
Trials)
The map derived from the classifier trained to discriminate
MPH from ATX on the delay component of rewarded trials
(Figure 7) contained distributed patterns favoring MPH and
ATX. The pattern favoring MPH was mainly localized to
WM regions (IPS and lateral PFCFBA 9/46) and the
pattern favoring ATX was mainly localized to the DMN.
Thus, during the delay component of rewarded trials, MPH
relative to ATX resulted in greater BOLD activity in WM
networks, and ATX relative to MPH resulted in greater
TRDs.
For all contrasts, the differential patterns derived from
GPC-RFE show a reasonably good correspondence to those
derived from an equivalent univariate SPM, except the SPM
retained substantially fewer voxels (at po0.001, uncor-
rected for multiple comparisons) than were retained by the
classifier (data not shown).
A concise summary of the results is provided in
Table 1.
DISCUSSION
We have shown differential effects of MPH and ATX on
brain activity patterns in healthy volunteers performing a
rewarded WM task. An important conclusion from our
results is that the effects of MPH and ATX on WM are
context-dependent. In the rewarded context, both MPH
and ATX could be accurately discriminated from PLC
across all task components, showing similar patterns of
attenuation across the WM networks and enhanced TRDs.
During the encoding component of non-rewarded trials,
MPH, but not ATX, could be discriminated from PLC; MPH
increased activity in WM regions and attenuated TRDs
compared with PLC. The pattern of BOLD signal changes
Figure 6 Gaussian process classifier (GPC)-recursive feature elimination (RFE) distribution maps for classifiers discriminating between methylphenidate
(MPH) and placebo (PLC) for the encoding working memory (WM) component (non-rewarded trials). A distributed pattern favoring MPH can be observed
that indicates that during encoding and in a non-rewarded context MPH enhanced activity in some WM regions and enhanced task-related deactivation
(TRDs) in default mode network (DMN) regions.
Figure 7 Gaussian process classifier (GPC)-recursive feature elimination (RFE) distribution maps for classifiers discriminating between methylphenidate
(MPH) and atomoxetine (ATX) for the delay component of rewarded trials. Distributed patterns of activity favoring both MPH and ATX can be observed
that indicate that in a rewarded context: (1) MPH enhanced activity throughout working memory (WM) networks relative to ATX and (2) ATX enhanced
task-related deactivation (TRDs) in default mode network (DMN) regions.
Table 1 Summary of Classification Results
Contrast WM components exceeding chance Neuronal effects Figure(s)
Reward vs control Encoding, delay and retrieval for all drug
contrasts, except for encoding on MPH
Reward increased activity in WM
networks and suppressed TRDs
Figure 3, Supplementary Figure S2
ATX vs PLC (rewarded trials) Encoding, delay and retrieval ATX decreased activity in WM
networks and enhanced TRDs
Figure 4
ATX vs PLC (non-rewarded trials) None F Supplementary Figure S3
MPH vs PLC (rewarded trials) Encoding, delay and retrieval MPH decreased activity in WM
networks and enhanced TRDs
Figure 5
MPH vs PLC (non-rewarded trials) Encoding only MPH increased activity in WM
networks and suppressed TRDs
Figure 6
MPH vs ATX (rewarded trials) Delay only MPH had greater activity in WM
regions relative to ATX and ATX
resulted in greater TRDs
Figure 7
MPH vs ATX (non-rewarded trials) None FF
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also discriminated MPH from ATX. In this context, and
relative to ATX, MPH produced a pattern of increased
activity in WM networks, whereas ATX produced greater
activity in the DMN. Overall this complex set of findings
suggests that: (1) both MPH and ATX have salient effects
during rewarded WM in both task-activated and deactivated
networks; (2) during the delay component of rewarded
trials, MPH and ATX had opposing effects on activated and
deactivated networks; and (3) MPH may mimic reward
during encoding.
The results in this study were determined by applying
recently developed PR techniques to the neuroimaging data,
which afford substantially greater sensitivity than conven-
tional mass-univariate techniques (Haynes and Rees, 2006;
Norman et al, 2006) by making use of spatial correlation
between voxels, lending themselves well to whole-brain
inference. These properties make PR ideally suited to drug
discrimination studies, where drugs administered systemi-
cally can theoretically influence distributed brain regions
owing to direct effects at target receptor sites and
consequent effects on connected brain regions. It is
important to emphasize that multivariate brain maps
derived from PR analysis provide a different perspective
to mass-univariate analysis and should be interpreted
differently. In particular, multivariate brain maps describe
a pattern of activity, and coefficients should not be
interpreted as representing focal effects because many brain
regions potentially contribute to the accuracy of the
classifier.
The WM networks identified in this study agree well with
previous studies (Curtis et al, 2004; Gibbs and D’Esposito,
2005) and were sensitive to reward. During rewarded trials
participants performed the task more accurately, which was
reflected as a generalized pattern of increased brain activity
throughout WM networks and in the DMN. Indeed,
increased activity in WM brain regions is a known effect
of reward on WM tasks (Pochon et al, 2002; Taylor et al,
2004; Pessoa and Engelmann, 2010) and may reflect an
increase in neuronal effort.
MPH and ATX did not alter performance accuracy or
response latency during the WM task. However, previous
studies using MPH and amphetamine have suggested that
reductions in BOLD activation accompanied by equivalent
behavioral performance reflect an increased efficiency of
WM networks (Mattay et al, 2000; Mehta et al, 2000). Thus,
for our data in a rewarded context, this would seem to be
the most parsimonious explanation for the effects of MPH
and ATX on task activation and deactivation networks. This
effect is probably mediated by increased catecholamine
concentrations in WM regions (Bymaster et al, 2002), which
is known to focus neuronal activity by enhancing responses
to task-relevant stimuli while suppressing background noise
(Foote et al, 1975; Seamans et al, 2001). Historically, DA has
been linked with WM performance through increasing the
efficiency of PFC neurons by decreasing delay-related
response to ‘noise’ (Arnsten, 2007; Vijayraghavan et al,
2007) and the stabilization of their sustained activity
(Durstewitz et al, 2000). However, NA is probably also
important as therapeutic doses of MPH increase PFC
extracellular concentrations of NA substantially more than
DA (Berridge et al, 2006), and the beneficial effects of MPH
and ATX on WM can be blocked by either DA D1 or NA a2
receptor antagonists (Arnsten and Dudley, 2005; Gamo
et al, 2010). NA is also known to increase delay-related
activity of PFC neurons in response to ‘signals’ (Arnsten,
2007) and increase the salience of novel stimuli, leading to
the suggestion that it serves as an alarm system for
contextual changes (Yu and Dayan, 2005).
The PCC, precuneus, and ventromedial PFC are known to
show decreased activity during a wide range of goal-
directed tasks (Shulman et al, 1997). These regions have
been proposed to underlie a ‘default mode’ of brain
function (Raichle et al, 2001) and it is thought that to
facilitate goal-directed action, task-irrelevant mental activ-
ity in these regions must be suppressed. Indeed, failure to
suppress default mode activity reflects momentary lapses in
attention (Weissman et al, 2006), resulting in increased
probability of error (Eichele et al, 2008). There is also
preliminary evidence that ADHD may be characterized by
deficiencies in attentional focus and insufficient suppres-
sion of brain activity in focal regions of the DMN
(Fassbender et al, 2009) and that MPH may normalize the
amplitude of TRDs in treatment-responsive ADHD partici-
pants (Peterson et al, 2009). Our results are consistent with
this interpretation and further show that suppression of
task-irrelevant mental activity may be a mechanism
common to both MPH and ATX. Importantly, this effect
was context-dependent, as it was only observed during
rewarded trials.
In a rewarded context, classification accuracy was
equivalent for classifiers discriminating MPH or ATX from
PLC for each WM component, although accuracy was
slightly higher for both drugs during retrieval relative to
encoding and delay. Qualitatively, the effects of MPH and
ATX were comparable, with both drugs producing a
generalized decrease in brain activity in WM networks
and DMN (ie, attenuation of activity in WM networks and
enhancement of TRDs). Nonetheless, the extent of these
effects separated the drugs during the delay component of
rewarded trials: ATX attenuated BOLD activity in WM
networks more than MPH and MPH enhanced TRDs more
than ATX.
Microdialysis studies in rodents have shown that MPH
and ATX increase DA concentration in the PFC, but only
MPH increases DA in the striatum (Bymaster et al, 2002),
and that therapeutic doses of MPH increase catecholamine
concentration in the PFC substantially more than that in the
striatum (Berridge et al, 2006). However, in our study we
did not observe increased striatal activity following MPH,
similar to other neuroimaging studies in healthy volunteers
(Mehta et al, 2000; Udo de Haes et al, 2007). This may be
because the WM task we employed does not substantially
engage the striatum, even for rewarded trials (Supplemen-
tary Figure S2), which is consistent with a recent review of
the effects of reward on WM (Pessoa and Engelmann, 2010)
or simply because the consequential effects of MPH on
striatal DA levels are expressed in connected brain regions.
Thus, subcortical effects of MPH on DA remain a candidate
mechanism for the differential effects of MPH and ATX, as
the PFC and striatum are strongly connected by parallel
corticostriatal circuits (Alexander et al, 1986), and there is
emerging evidence suggesting that the striatal DA system
plays a role in the modulation of the DMN (Kelly et al, 2009;
fMRI patterns for methylphenidate and atomoxetine
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ing striatal DA release and its functional consequences on
brain activity are required to test this hypothesis explicitly.
In a non-rewarded context, it was only possible to
discriminate MPH from PLC during encoding. In this case,
the differential pattern (Figure 6) bears a strong qualitative
resemblance to that differentiating rewarded from non-
rewarded trials (Figure 3), suggesting that while MPH did
not improve performance at the dose administered, MPH
nevertheless mimics the reward effect. Discrimination
accuracies for classifiers contrasting rewarded and non-
rewarded trials were also consistently lower on MPH than
on ATX or PLC and did not exceed chance for encoding,
indicating that activity patterns discriminating reward and
non-rewarded trials were less distinguishable on MPH
(Figure 2a), which is consistent with the suggestion that
MPH increases task salience (Volkow et al, 2004). This
effect is probably mediated by DA, because a learned
association between a cue and a reward results in increased
phasic dopaminergic firing during cue presentation not
reward delivery (Schultz et al, 1993) and increased
dopaminergic firing, often followed by immediate depres-
sion, is also associated with stimuli that resemble the
rewarded stimulus (Schultz and Romo, 1990). Catechola-
minergic signalling has also been associated with an
‘inverted-U’ dose–response relationship in the PFC (Arn-
sten, 2006; Levy, 2009) with optimal PFC function at
intermediate concentrations and too much or too little DA
or NA resulting in impaired PFC function. Although
speculative at this stage, such a relationship may underlie
different contextual effects of MPH, where rewarded and
non-rewarded contexts may engage curves with different
optimal dosing. Also, we only administered one dose of
each drug here, so it is possible that ATX shares the reward-
emulating effect at a different dose, which could addition-
ally account for the classifier’s inability to discriminate
MPH and ATX during encoding of non-rewarded trials
(Supplementary Figure S4).
Individual differences in response to drug administration
may be an interesting line of future research. In particular,
genetic factors influence responses to stimulants (Mattay
et al, 2003), and although we did not collect genetic
information here, inclusion of genetic factors can only be
expected to improve predictive performance. As noted, only
one dose of each drug was administered so that dose effects
cannot be excluded as confounds, but three lines of
evidence speak against this possibility: first, administered
doses were matched according to doses used in clinical
practice. Second, motor-evoked potentials were altered to a
similar extent for both drugs using identical doses to those
administered here (Gilbert et al, 2006). Third, opposing
effects of MPH and ATX on activated and deactivated task
networks during the delay component of rewarded trials are
difficult to explain by a simple dose effect.
In summary, we accurately discriminated the effects of
MPH and ATX on rewarded and non-rewarded WM
networks using multivariate PR. We suggest that this
method is ideal for drug discrimination studies because
for most psychotropic medications subtle distributed effects
probably predominate over strong focal effects. More
importantly, our results show that MPH and ATX have
effects on WM function that are context-dependent and
suggest that the interaction between drug effects and
motivational state will be crucial in defining the beneficial
effects of MPH and ATX in ADHD.
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